Our study illustrated that the representative PRAPi drug niraparib, restrained PCa cell proliferation, migration and invasion and delayed tumor growth in mice by regulating the MEG3/miR-181-5p/GATA6 pathway. Here, MEG3 is linked to neoplasm.